omega-3 pill decreases cardiac events (REDUCE-IT trial)
A recent trial released at the 2018 Am Heart Assn meetings found that an eicosapentanaenoic acid (EPA) derivative (a fish oil variant) decreased cardiovascular outcomes in patients with high cardiovascular risk, had high triglyceride levels, and were already on a statin with low LDL levels (see cad triglyc reduct benefit nejm2018 in dropbox, or DOI: 10.1056/NEJMoa1812792) Details: --8179 patients were enrolled, all with established cardiovascular disease or with diabetes and at least one other risk factor, on statin therapy with LDL 41-100 mg/dL, but ha d a fasting triglyceride (TG) level of 135-499 mg/dL --median age 64, 71% male, 90% white, BMI 31, 71% from US/Canada/Netherlands/Australia/New Zealand, 26% Eastern Europe, 100% on statins / 6% ezetimibe, 58% diabetes --71% of the patients were enrolled for secondary prevention, 29% primary prevention of cardiovascular events --median hs-CRP 2.2...